100058-61-5Relevant articles and documents
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties
Kohn, Todd J.,Du, Xiaohui,Lai, Sujen,Xiong, Yumei,Komorowski, Renee,Veniant, Murielle,Fu, Zice,Jiao, Xianyun,Pattaropong, Vatee,Chow, David,Cardozo, Mario,Jin, Lixia,Conn, Marion,DeWolf, Walter E.,Kraser, Christopher F.,Hinklin, Ronald J.,Boys, Mark L.,Medina, Julio C.,Houze, Jonathan,Dransfield, Paul,Coward, Peter
, p. 666 - 670 (2016)
Two 1-(4-aryl-5-alkyl-pyridin-2-yl)-3-methylurea glucokinase activators were identified with robust in vivo efficacy. These two compounds possessed higher solubilities than the previously identified triaryl compounds (i.e., AM-2394). Structure-activity re
COMPOUNDS AND USES THEREOF
-
Page/Page column 356, (2021/08/06)
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
MERTK DEGRADERS AND USES THEREOF
-
Paragraph 00827, (2020/01/31)
The present invention provides compounds, compositions thereof, and methods of using the same.
CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS
-
Page/Page column 395, (2019/10/23)
The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.